A clinicopathological follow-up study including sequential bone marrow biopsies was performed on 79 patients with idiopathic (primary) myelofibrosis (IMF) to characterize initial (prefibrotic) stages and to elucidate whether development of fibrosis was accompanied by corresponding clinical findings. For this purpose our cohort of patients was divided into two groups of which the first presented with the generally accepted signs and symptoms of IMF (group I; n = 60). Most patients of the second group (group II; n = 19) showed mild to moderate therapy-refractory anemia, minimal to slight splenomegaly and frequently thrombocytosis, but no bone marrow fibrosis at onset. Hematopoiesis was consistent with a striking hypercellularity in comparison to the age-related involution by adipose tissue, a conspicuous clustering and histotopographic dislocation of megakaryocytes, a neutrophil granulocytic proliferation and a reduction of erythropoietic islets with arrest of maturation. Most remarkable was the dysplastic cytology of megakaryocytes with a definitive deviation of differentiation resulting in bizarre forms. Follow-up examinations revealed that at later stages group II patients were not distinguishable from the first group with more advanced IMF. For this reason, these patients were regarded as presenting initial, prefibrotic IMF characterized by distinctive bone marrow features at the beginning. The prominent abnormalities of megakaryopoiesis together with the granulocytic proliferation were extremely helpful to differentiate prefibrotic IMF with accompanying thrombocythemia from essential thrombocythemia (ET). Dynamics of fiber progression were calculated by regarding increase in density per time. Speed of progression during the first year of observation proved to be significantly higher in group II patients with prefibrotic IMF in comparison to fullblown cases (group I). In conclusion, with respect to prospective clinical trials, diagnostic criteria for IMF should be re-evaluated by also taking initial, prefibrotic stages into account.
Introduction
There is general agreement that diagnosis of idiopathic (primary) myelofibrosis (IMF) or agnogenic myeloid metaplasia with myelofibrosis should be established by the following criteria: splenomegaly, leuko-erythroblastosis with tear drop poikilocytosis (dacryocytosis), anemia, reticulin or collagen fibrosis of the bone marrow and the absence of a Philadelphia chromosome. [1] [2] [3] [4] In leading review articles and clinical studies some degree of myelofibrosis is explicitly emphasized as one of the basic requirements for this condition. 2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Despite these obviously stringent criteria, in a number of studies patients with postpolycythemic myeloid metaplasia with myelofibrosis 3, 5 or acute (malignant) myelosclerosis were included. 16, 17 Moreover, a conflict of opinion still persists when addressing: (1) gression of bone marrow fibrosis. In this context it is frequently questioned, whether changes in bone marrow morphology are reflected not only by a stepwise occurring fibrous replacement of hematopoiesis, but also by corresponding clinical data. The pertinent literature contains discordant findings or little supportive evidence for the latter assumption based on long-term follow-up and sequential bone marrow examinations. These controversies are mirrored by descriptions recording no relevant alterations in a considerable number of patients, 5 ,17,18 a progression 19 or occasionally even a reversal of myelofibrosis following cytoreductive [20] [21] [22] or interferon therapy. 23 On the other hand, histopathology provided the first tangible evidence for a gradual evolution of medullary fibrosis associated with an increased growth of abnormal megakaryocytes. [24] [25] [26] In these studies bone marrow alterations were regarded as progressive, ranging from early-hypercellular lesions without, or only minimal, reticulin fibrosis merging into advanced and terminal stages characterized by gross collagen accumulation and osteosclerosis. 25, 27 In this context the question remains open, how to diagnose the initial-early stages of IMF and whether these changes are specific, occur with time and are accompanied by corresponding clinical data. In this investigation an attempt was made to characterize these 'prefibroticinital stages' of IMF by proper evaluation of laboratory and histomorphological findings as well. For this reason, a comparative follow-up study was carried out including sequential bone marrow biopsies from two groups of patients: one group with classical signs and symptoms of IMF [1] [2] [3] [4] [5] [6] [7] [8] and another lacking relevant myelofibrosis and some of the diagnostic clinical criteria on admission.
Materials and methods

Patients
We studied two groups of patients with sequential biopsies of the bone marrow and complete office and hospital records.
The first cohort (group I) encompassed 60 patients (26 males, 34 females; median age 61 years) presenting with the definitive signs and symptoms of IMF. [1] [2] [3] [4] 8, 11 These generally accepted diagnostic criteria for eligibility included: (1) splenomegaly; (2) anemia; (3) leuko-erythroblastic blood picture with dacryocytes; (4) myelofibrosis -at least by reticulin fibers accompanied by abnormal megakaryocyte proliferation; (5) no allied or preceding myeloproliferative disorder; (6) no Philadelphia chromosome. Treatment of this group was based on age, poor performance status and extent of cytopenia. More precisely, according to major treatment modalities (including combinations), 11 patients received no therapy and 23 patients had supportive care only (essential transfusions of packed cells and/or corticosteroids) and antiplatelet agents (19 patients) . Moreover, 20 patients received oral chemotherapy (busulfan, hydroxyurea), one patient underwent interferon Table 1 Clinical and laboratory data (mean ± s.d., ranges in brackets for first biopsies) at first presentation and at the time of last (2nd to 5th) biopsy in our two groups of patients presenting with different stages of IMF treatment and three patients a splenectomy or splenic irradiation, usually when all other regimes failed. The second group (group II) consisted of 19 patients (nine males, 10 females; median age 58 years) complaining of fatigue, general malaise and occasionally about night sweats, easy bruising, weight loss, abdominal distress. In this cohort bone marrow biopsy has been performed with the presumptive clinical diagnosis of therapy-refractory anemia, splenomegaly, thrombocytosis of unknown origin, 'unclassifiable' myeloproliferative disorder or essential thrombocythemia (ET). Re-evaluation of physical findings showed that most of these patients presented with: (1) minor to moderate splenomegaly; (2) borderline to slight anemia; (3) rarely a few erythroid precursor cells and dacryocytes in the peripheral blood films; (4) a frequently elevated platelet count exceeding 500 × 10 9 /l; (5) no preceding or allied myelo-or lymphoproliferative disorder; (6) no Philadelphia chromosome. However, initially in this group diagnostic criteria of manifest IMF [1] [2] [3] [4] were not completely fulfilled, in particular because of absence of relevant (reticulin) fibrosis. On the other hand, other bone marrow features (megakaryocytes, granulopoiesis) which are described in detail later were consistent with the appearance in group I patients. Treatment of this second group was similar to the first one and frequently included also antiplatelet agents alone (aspirin/dipyridamole) or in combination with the other drugs. In both groups of patients minimal follow-up was 6 months ranging up to 10 years (mean 5.5 years) with a deadline at 1 September 1998.
Bone marrow biopsies
Representative trephine biopsies of the bone marrow (mean size 14 × 1.2 mm) were performed from the posterior iliac crest. 28 At a minimal interval of 6 months in all patients two repeated examinations were done, in 25 patients three and in 13 patients up to five biopsies during the course of disease (Table 1) . Median interval between first and last biopsy was 16 months. Fixation was carried out in an aldehyde solution for 12-48 h (2 ml 25% glutaraldehyde, 3 ml 37% formaldehyde, 1.58 g anhydrous calcium acetate, and distilled water per 100 ml). Further processing included decalcification for 3-4 days in 10% buffered ethylen-diamine tetra-acetate acid (EDTA), pH 7.4, paraffin embedding, and employment of several routine staining techniques 29 involving Giemsa, PAS (periodic acid Schiff reagent), naphthol-AS-D-chloroacetate esterase, Perl's reaction for iron and a silver impregnation method (Gomori's stain). For a specific identification of megakaryocytes and erythropoiesis including precursor cells, appropriate monoclonal antibodies (Y2/51-CD61 and Ret 40f) were selected and staining methods applied, as described in detail elsewhere. 30 
Morphometry
Morphometric analysis was performed by a manual optic planimeter (VIDAS-Zeiss-Kontron) with a standard program set (Videoplan software) on large biopsy specimens with an artefact-free mean marrow area of 9.6 ± 5.0 mm 2 . Reticulin and collagen (argyrophilic) fiber density was measured following silver impregnation (Gomori's stain) by counting the number of intersections with the lines of a grid ocular at a magnification of ×500 in at least 25 randomly selected fields free from trabecular bone (so-called point-intersection method). The area covered by fat cells was subtracted and fiber density expressed as number of intersections (i ) per square millimeter hematopoietic tissue-cellularity (i/mm 2 ) and also per total bone marrow including adipose tissue. Because of the significantly varying intervals between sequential biopsies in both groups and in individual patients, assessment of progression of myelofibrosis had to be carried out in relation to time and quantity. In this way, dynamics of myelofibrosis were characterized by calculating the so-called myelofibrosis progression index (MPI) consisting of the ratio between difference in fiber density (⌬ fibers i × 10 2 /mm 2 ) and time-interval in months between first and last bone marrow biopsy. Statistical evaluation included calculation of Student's t-test for significant differences regarding various hematological and morphometric parameters between group I and II patients.
Results
Clinical findings of our group I patients revealed features which were generally compatible with manifest IMF including anemia, mild leukocytosis, a frequently occurring leukoerythroblastic blood picture with tear drop erythrocytes and hepatosplenomegaly in the majority of patients (Table 1) . A thrombocyte count in excess of 1000 × 10 9 /l was recognized in only four of 60 patients (7%). Following repeated bone marrow examinations at varying intervals laboratory data showed significant changes concerning degree of anemia, splenomegaly, thrombocyte count and frequency of erythro-myeloblasts in the peripheral blood (Table 1) . On the other hand, the 19 patients of group II, who were regarded as presenting with initial-prefibrotic IMF exhibited a borderline to mild anemia and only minor to slight splenomegaly. An elevated thrombocyte count greater than 1000 × 10 9 /l was observed in eight patients (36%). However, at time of the terminal biopsy (median interval 16 months) hematological findings were not significantly different compared to group II patients with definite IMF at onset (Table 1) . Hence, at this point of the lengthy disease process according to presenting clinical features group II patients were not distinguishable from group I patients with classical signs and symptoms of IMF.
At the beginning bone marrow specimens in group II patients with initial (prefibrotic) IMF showed a striking hypercellularity considering the age-related involution by adipose tissue in an elderly population (Figure 1a ). There was a leftshifted and hyperplastic neutrophil granulopoiesis in addition to small clusters of erythroblasts and a very prominent proliferation of megakaryocytes (Figure 1a) . Especially in the six patients with a leukocyte count exceeding 20 × 10 9 /l granulopoiesis was strikingly enhanced, but except for a predominance of pro-and metamyelocytes revealed no relevant cytological abnormalities. Megakaryopoiesis was not only characterized by a conspicuous clustering (Figure 1b) , but also by a bizarre, dysplastic appearance consistent with abnormalities of nuclear-cytoplastic maturation and striking differences in size and shape (Figure 1c) . A prominent growth of megakaryocytes was usually associated with an increase in the platelet count. In many patients erythropoiesis revealed an apparent arrest of maturation, ie a relative prevalence of proerythroblasts and early erythroblasts in the islets, however, without obvious tendency for a continuous differentiation into later precursor forms (Figure 1d , e). Patients with a hemoglobin level less than 12 g/dl often showed an overall reduction in the amount of erythroid precursors and occasionally, in addition to the already described features, a macrocytic aspect. Although reticulin-stained fibers were not increased in group II patients at onset -first biopsy (Figure 2a) , myelofibrosis gradually evolved in sequential examinations at significantly varying rates and intervals (Table 2, Figure 2b) . A close contact of reticulin fiber bundles with clusters of abnormal megakaryocytes was a regular finding in these cases (Figure 2b ), like the development of minor to gross osteosclerosis with growth of endophytic woven and neospongious bony trabeculae (Figure 2c, d ). According to morphometric analysis an overall increase in fiber density was detectable in group I and II patients alike (Table 2 ). However, a closer look revealed that an only borderline to minimal progression of myelofibrosis during observation time was found in 24 patients of group I, and in six patients of group II. In this context it has to be noted that none of both groups displayed a significant regression of fiber density during low-dose chemotherapy (busulfan, hydroxyurea). Dynamics of myelofibrosis were properly expressed by the MPI (Table 2) to standardize the varying endpoints of bone marrow examinations. Calculation of this factor further disclosed that relative increase in fiber density per year (Figure 3 ) was greatly enhanced in group II (1.52 ± 2.61) with prefibrotic IMF in comparison to group I Table 2 Amount of argyrophilic (reticulin-collagen) fibers (mean ± s.d.) at first presentation and at the time of the last (2nd to 5th) biopsy (median interval 16 months) in our two groups of patients .
Figure 3
Relative increase in fiber density per first year of observation expressed by the abstract myelofibrosis progression index (MPI) in group I vs group II patients. This index reveals an enhanced speed in group II patients with prefibrotic stage of IMF (1.52 ± 2.61; range 0. 21-8.18 ) demonstrable by the significant increase in skewness compared to group I patients (0.81 ± 3.36; range 0.18-16.57).
(0.81 ± 3.36) patients. Therefore speed of progression of myelofibrosis proved to be significantly different in both cohorts. In line with the finding of an initial stage of disease in group II patients (prefibrotic IMF) opposed to those with full-blown IMF (group I) at diagnosis relevant differences were observed concerning the outcome (Table 1) .
Discussion
From the clinical point of view, IMF is a heterogeneous disease in terms of presentation and evolution ranging from nearly asymptomatic patients corresponding with several of our group II to others with strikingly expressed clinical features derived from severe anemia and significant splenomegaly as shown in group I patients. 1, 31 Only very recently changing profiles in presenting features of patients with IMF have been recognized, which indicated a trend towards a less florid clinical picture according to the overall expression of hematological findings. 32 This fact implies an awareness of early stage IMF by the clinicians and as a consequence may lead to a reconsideration of the generally applied diagnostic criteria. [1] [2] [3] [4] [5] [6] [7] Corresponding criteria have already been regarded by the newly introduced so-called Cologne Classification, in particular to avoid a confusion of ET and thrombocythemias occurring in early-hypercellular stages of IMF. 33 This differen-tiation is a crucial point, because a considerable number of patients with prefibrotic IMF may present with significantly elevated platelet counts ( Table 1) . As has been listed in Table  3 certain bone marrow features, in particular megakaryopoiesis are an invaluable aid in discriminating prefibrotic-early IMF from ET. On the other hand, contrasting ET, in IMF the high thrombocyte level is not sustained and follow-up studies usually reveal a spontaneous regression of thrombocythemia. Moreover, these changes are normally accompanied by increasing anemia and splenomegaly and also by a leukoerythroblastic blood picture including tear drop erythrocytes. In keeping with these diagnostic features the updated diagnostic criteria for ET by the Polycythemia Vera Study Group 34 which are widely accepted and generally applied in leading clinical studies should be re-evaluated. This has already been taken into account by including also histopathology in addition to 'collagen fibrosis of marrow absent or Ͻ1/3 of biopsy area' 34 into corresponding sets of diagnostic requirements. 35 In comparison to IMF with or without associated thrombocythemia only minor changes in the histological pattern can be shown in follow-up biopsies in ET patients under no or minimal treatment. In a pertinent article on this subject of the 575 patients with ET evaluated in a referral center only 1% presented with and 5% developed a reticulin fibrosis within 5 years. 26 Opposed to IMF with a median survival of 3.5-5.5 years in larger series of patients 7, 9, 10, 12, [13] [14] [15] 36 prognosis in ET is significantly more favorable. Survival has been reported to range between 12 to 14 years, thus implicating no difference compared to the life expectancy in a sex-and age-matched normal population. 9, 33 For this reason, an unequivocal discrimination between initial-early stages of IMF with thrombocythemia and ET is warranted and may be easily accomplished by a synoptical approach regarding equally clinical findings and histopathology (Tables 1, 3) .
Laboratory findings or histopathology of the bone marrow in initial-prefibrotic IMF including their mutual correlations have relatively rarely come to the attention of the clinicians. Exceptions were a few studies which have been primarily focused on morphology. In this context corresponding alterations of the bone marrow were labelled with the descriptive term (chronic) megakaryocytic-granulocytic proliferation or myelosis (CMGM) and shown to exist in about 20% of all IMF cases. [24] [25] [26] [27] 37 With reference to the current literature, abnormalities of the megakaryocytic lineage were only marginally mentioned. 2, 4, 8, 11, 31 It should be kept in mind that atypical megakaryopoiesis is not only the hallmark of this disorder, but as has been outlined in Table 3 presents a most prominent point of differentiation from ET. 27, 33 In prefibrotic IMF a slightly increased neutrophil granulopoiesis is in keeping with the minor to moderate leukocytosis and in many patients the obviously arrested erythropoiesis corresponds with a mild therapy-refractory anemia. Altogether these features are not prominent in the bone marrow of patients with ET or polycythemia rubra vera (PV) 34 and thus may serve as further diagnostic means of distinction. Onset of reticulin fibrosis initiates with a thickening of the sinus walls (sinus wall sclerosis) and further reveals a strikingly close contact of the fibrous network with the abnormal clusters of dysplastic megakaryocytes. [24] [25] [26] [27] 37 Therefore morphological phenomena reflect the complex functional involvement of the megakaryocytic lineage in the generation of major constituents of the myelofibrotic stroma (collagen types I, III and IV). 11, [38] [39] [40] Regarding the progression of myelofibrosis in several previously published studies, inconclusive results have been recorded ranging from no change, regression or increase with time. 5, [17] [18] [19] [20] [21] [22] [25] [26] [27] Besides the well-known difficulties to determine the exact amount of fibers in bone marrow specimens (semiquantitative grading vs morphometry), 25, 26, 33, 37 a number of factors may have acted conversely to explain these significantly discordant findings. As has already been pointed out, intervals between initial to terminal examinations ranged from several months to years. 25 Moreover, criteria for entry into these studies included patients with postpolycythemic myeloid metaplasia-myelofibrosis 5, 17 or acute (malignant) myelofibrosis. 16, 17 Finally, it should be emphasized that reversal of fibrosis may be simulated by an expansion of adipose tissue, in particular in the more advanced stages of IMF or as the sequel of cytoreductive therapy. For this reason, the problem of documenting changes in the extent of myelofibrosis can only be solved by a comprehensive study design including not only clear-cut cases of IMF, but also an appropriate methodology of histopathological evaluation. This procedure enables a recognition of subtle alterations and further allows a reference to time. A more elaborate evaluation of dynamics characterizing this process has been carried out in this study by calculation of the MPI. Considering this index, it was shown that speed of progression of myelofibrosis was enhanced in prefibrotic-early IMF contrasting the more advanced stages (group I patients).
In conclusion, clinicopathological studies during the last decade have greatly increased our understanding of the complexity of the disease process in IMF. The failure to recognize initial stages of this condition more explicitly may have been influenced by the significantly varying intervals and unpredictable nature of this stage-like process and also by a certain neglect of bone marrow histopathology. Therefore modern concepts and study designs of clinical trials should be aware of early prefibrotic IMF to cover the wide spectrum of disease manifestation.
